The deal marks the latest in a series of distribution agreements MDxHealth has recently signed for the SelectMDx test.
The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.
The insurer operates Blue Cross and Blue Shield plans in Illinois, Montana, New Mexico, Oklahoma, and Texas, and will now cover ConfirmMDx for its customers.
The positive insurance coverage decision for ConfirmMDx is one of several the company has received in recent months.
Biotechnology company SouthGenetics will distribute the prostate cancer test in countries including Argentina, Chile, Mexico, Peru, Panama, and Venezuela.
The European Health Centre Innovation will now distribute SelectMDx and ConfirmMDx to its urology customers throughout the country.
The positive coverage determination is one of several the company has received in recent months from various insurance companies for the ConfirmMDx test.
With the inclusion of ConfirmMDx in the Medi-Cal program, MDxHealth will seek access for the test in other state Medicaid programs.
The urine-based test is designed to identify men at high risk for aggressive prostate cancer, as well as those at low risk for the disease.
In the second half of the year, the firm plans to introduce a urine-based bladder cancer test and achieve sales growth between 30 and 50 percent.
In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.
Technology Review points out that a new US presidential science advisor hasn't been selected.
Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.
President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.